Table 3.
Univariate survival analysis in stage II and III patients
| Univariate survival analysis | p-value | |
|---|---|---|
| Probability of DFS (95%CI) | ||
| Adjuvant Chemotherapy | ||
| Yes | 61.4% (51.7–71.1%) | |
| No | 46.3% (36.1–56.5%) | 0.001 |
| CIMP status | ||
| Positive | 56.3% (43.9–68.7%) | |
| Negative | 53.0% (44.3–61.7%) | 0.8 |
| TNM stage | ||
| II | 60.2% (50.8–69.6%) | |
| III | 46.6% (36.0–57.2%) | 0.02 |
| Age | ||
| ≤60 | 74.2% (58.5–89.9%) | |
| >60 | 50.0% (42.1–57.9%) | 0.02 |
| Microsatellite instability | ||
| Stable | 52.6% (45.1–60.1%) | |
| Unstable | 65.2% (42.7–87.7%) | 0.2 |
| BRAF mutation | ||
| Mutated | 42.8% (13.8–66.2%) | |
| Not mutated | 55.6% (52.5–67.5%) | 0.8 |
| Gender | ||
| Male | 51.8% (44.1–59.5%) | |
| Female | 56.8% (47.2–66.4%) | 0.7 |
| Univariate survival analysis according to treatment received | ||
| Probability of DFS (95%CI) | p-value | |
| CIMP + patients (n=64) | ||
| Adjuvant chemotherapy | 57.7% (38.3–77.1%) | 0.7 |
| No adjuvant chemotherapy | 68.4% (53.3–83.5%) | |
| CIMP – patients (n=132) | ||
| Adjuvant chemotherapy | 80.0% (70.8–89.2%) | 0.00001 |
| No adjuvant chemotherapy | 45.6% (32.4–58.8%) | |
| Univariate survival analysis according to CIMP status | ||
| Probability of DFS (95%CI) | p-value | |
| Adjuvant chemotherapy (n=101) | ||
| CIMP + | 57.7% (38.3–77.1%) | 0.02 |
| CIMP − | 80.0% (70.8–89.2%) | |
| No adjuvant chemotherapy (n=95) | ||
| CIMP + | 68.4% (53.3–83.5%) | 0.04 |
| CIMP − | 45.6% (32.4–58.8%) | |
p-value: log-rank test